Research
Hormonal
GLP-1 receptor agonists and dual receptor agonists effectively counteract hyperglycemia and obesity.
These medications may be prioritized in treatment plans for T2D patients with obesity.
StrongSupportsmedium confidence
GLP-1 RAs and the new class of GLP1 and gastric inhibitory polypeptide dual RAs counteract 2 of these metabolic defects of T2D, hyperglycemia and obesity.
Why this rating
The abstract provides a strong basis for the claims about these medications.
Source
New Horizons: Emerging Antidiabetic Medications
Geltrude Mingrone et al. · The Journal of Clinical Endocrinology & Metabolism · 2022
reviewCited 18×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →